Determine the baseline characteristics of patients who have recurrent symptomatic genital herpetic disease Determine the acceptance to patients of clinical trial procedures Determine interest in participation in genital herpes vaccine trials

Inclusion Criteria:

• Able to understand and willing to sign the informed consent document.
• Patient confirmation of a diagnosis of HSV-2 infection at least 2 years prior to inclusion. Laboratory confirmation is not required.
• Symptomatic recurrent genital herpetic disease for >2 years supported by compatible clinical history

Exclusion Criteria:

• Subjects who do not meet the inclusion criteria for the study
• Subjects who are unable to provide legally effective informed consent

Patients with recurrent symptomatic of genital herpes